Business
Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings
$56.2 million in proceeds from completed public offering and concurrent private equity purchase by Medtronic and Ligand$55 million in proceeds and funding commitments from royalty-based, non-dilutive investments from Medtronic and LigandProceeds extend expected cash runway into the second half of 2027 and expected to fund completion of enrollment and follow up for the primary endpoint of the BACKBEAT study, as well as substantial enrollment of the Virtue Trial NEW HOPE, Pa., Aug. 05, 2025 (GLOBE
About this update from Ligand Pharmaceuticals Incorporated
[{"type":"image","alt":"Orchestra BioMed Holdings, Inc.","displaySize":"","headline":null,"caption":"Orchestra BioMed Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":97,"url":"https://media.zenfs.com/en/globenewswire.com/82bb98ef85c6f29f82627c7205a5e888"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PcUBlKSAoIj3BMZ.626pqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/82bb98ef85c6f29f82627c7205a5e888","width":300,"height":97},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/PcUBlKSAoIj3BMZ.626pqg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/82bb98ef85c6f29f82627c7205a5e888","width":300,"height":97}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"$56.2 million in proceeds from completed public offering and concurrent private equity purchase by Medtronic and Ligand","length":119,"tagName":"p"}]},{"val":[{"type":"text","content":"$55 million in proceeds and funding commitments from royalty-based, non-dilutive investments from Medtronic and Ligand","length":118,"tagName":"p"}]},{"val":[{"type":"text","content":"Proceeds extend expected cash runway into the second half of 2027 and expected to fund completion of enrollment and follow up for the primary endpoint of the BACKBEAT study, as well as substantial enrollment of the Virtue Trial","length":227,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":464,"olType":false},{"type":"text","content":"NEW HOPE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the successful completion of strategic transactions and concurrent public and private equity offerings totaling an expected $111.2 million in gross proceeds to support continued advancement of the Company’s late-stage atrioventricular interval modulation (“AVIM”) therapy and Virtue Sirolimus AngioInfusion Balloon (“SAB”) clinical programs.","length":604,"tagName":"p"},{"type":"text","content":"The aggregate $111.2 million in expected gross proceeds from transactions that formally closed or were committed to on August 4, 2025, is comprised of:","length":151,"tagName"...